Велика Британія - англійська - myHealthbox

caduceus pharma ltd - simvastatin - film-coated tablets - 40mg - hmg-coa reductase inhibitors - hypercholesterolaemia treatment of primary hypercholesterolaemia or mixed dyslipidaemia, as an adjunct to diet, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate treatment of homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid-lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate. cardiovascular prevention reduction of cardiovascular mortality and morbidity in patients with manifest atherosclerotic cardiovascular disease or diabetes mellitus, with either normal or increased cholesterol levels, as an adjunct to correction of other risk factors and other cardioprotective therapy

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - clobazam - oral suspension - 2 milligram(s)/millilitre - benzodiazepine derivatives; clobazam - anxiolytics - it is a 1,5-benzodiazepine indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, perizam must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. perizam may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

vale pharmaceuticals ltd - flucloxacillin sodium - pdr for soln inj/inf - 250 milligram - beta-lactamase resistant penicillins

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

vale pharmaceuticals ltd - flucloxacillin sodium - pdr for soln inj/inf - 500 milligram - beta-lactamase resistant penicillins

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

vale pharmaceuticals ltd - flucloxacillin sodium - pdr for soln inj/inf - 1000 milligram - beta-lactamase resistant penicillins

Ірландія - англійська - HPRA (Health Products Regulatory Authority)

vale pharmaceuticals ltd - flucloxacillin sodium - pdr for soln inj/inf - 2000 milligram - beta-lactamase resistant penicillins

Європейський Союз - англійська - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - antiemetics and antinauseants, , serotonin (5ht3) antagonists - aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Європейський Союз - англійська - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - atosiban (as acetate) - premature birth - other gynecologicals - atosiban is indicated to delay imminent pre-term birth in pregnant adult women with:regular uterine contractions of at least 30 seconds’ duration at a rate of ≥ 4 per 30 minutes;a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50%;a gestational age from 24 until 33 completed weeks;a normal foetal heart rate.

Європейський Союз - англійська - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.